CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.

Read more at globenewswire.com

Related news for (TCRR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.